Pharma BD Deal Intelligence
AstraZeneca divested its ex-U.S. anaesthetics portfolio (Diprivan, EMLA, and five other brands) to Aspen Global for $520M upfront and up to $770M total, letting AZ redeploy capital toward oncology. The assets became a durable, material cash-generator for Aspen, though a 2024 sale of EU rights to Sandoz signals later portfolio pruning.
Data-quality flag: this was AstraZeneca DIVESTING its anaesthetics portfolio TO Aspen Global — not AZ acquiring Aspen — but the underlying transaction aged as a clean win-win: AZ monetized non-core assets to fund oncology, and the portfolio became a durable, material cash-generating segment for Aspen.
Full analysis, sources & comparables →AstraZeneca's $770M ex-US anaesthetics handoff fits a 2016 asset-shedding pattern aligned with CEO Pascal Soriot's strategic focus on three core therapy areas…
Aspen's $770M acquisition of AZ's seven-product anaesthetics portfolio extends the South African specialty player's emerging-market commercial reach into…
The 2017 follow-on transaction (US rights) reinforced strategic intent — AZ ultimately divested all remaining anaesthetics rights to Aspen, completing the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca sold ex-U.S. commercialization rights for its seven-product anaesthetics portfolio to Aspen Global for $520M upfront plus up to $250M in product sales-related milestones, plus double-digit trademark royalties. Portfolio comprised Diprivan (general anaesthesia), EMLA (topical), and five local anaesthetics. Completed September 2016. Part of AstraZeneca's strategy to divest non-core mature assets.
Data-quality flag: this was AstraZeneca DIVESTING its anaesthetics portfolio TO Aspen Global — not AZ acquiring Aspen — but the underlying transaction aged as a clean win-win: AZ monetized non-core assets to fund oncology, and the portfolio became a durable, material cash-generating segment for Aspen.
Assessment window: 5yr post-close.
$5.3B Global general anaesthesia drugs market 2024 (USD) · $592M Portfolio global product sales 2015 (pre-deal)
General and local anaesthesia are foundational supportive-care interventions enabling the ~40-50M surgical and ~234M global major surgical procedures performed annually. Diprivan (propofol) remains the most widely used IV induction agent, while EMLA, lidocaine (Xylocaine), bupivacaine (Marcaine), ropivacaine (Naropin), mepivacaine (Carbocaine), and prilocaine (Citanest) cover the local/regional and topical anaesthesia continuum. The category is mature, genericized, and dominated by hospital tenders.
The anaesthetics category is dominated by genericized molecules: propofol (Diprivan and ~25%+ of generic propofol from Fresenius Kabi, Hospira/Pfizer, and Hikma), lidocaine (Xylocaine, plus generics from B. Braun, Pfizer, and Aspen), bupivacaine (Marcaine, plus generics), ropivacaine (Naropin), and topical EMLA (lidocaine/prilocaine). Sevoflurane and desflurane (AbbVie/Baxter) compete on the inhaled anaesthesia side. The 2016 transaction did not introduce a novel agent — it transferred ex-US commercialisation of seven established AstraZeneca brands (which generated $592M in 2015 sales) to Aspen, which already had Africa/EM distribution scale. AstraZeneca retained 10-year cost-plus manufacturing economics, preserving margin while shedding non-core commercial overhead. The competitive significance is not therapeutic — it is consolidation of the established anaesthetics franchise inside Aspen, sharpening AZ's portfolio focus on oncology, CV-renal-metabolic, and respiratory/immunology (per Pascal Soriot's stated rationale). The propofol segment alone was ~$1.35B globally in 2024 (Cognitive Market Research), with general anaesthesia drugs at ~$5.29B 2024 (Grand View) — generic erosion has been the dominant force since the deal closed. Source: https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-commercialisation-agreement-with-aspen-for-anaesthetic-medicines-portfolio-08062016.html
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Aspen Global Inc. (Aspen Pharmacare) (this deal) | 2016 | $770M | 69 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2016 deals · AstraZeneca PLC deals · Other deals